UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~the~~Report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported): June 22, 2026

~~Date~~Dare ~~of Report (Date of earliest event reported): June 11~~Bioscience, ~~2026~~Inc.

DARÉ BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36395

20-4139823

~~001-36395~~

~~20-4139823~~

(State or other jurisdictionof incorporation)

(CommissionFile Number)

(I.R.S. EmployerIdentification No.)

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

3655 Nobel Drive, Suite 260

San Diego, CA 92122

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 926-7655

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock		DARE		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨ ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ☐

Item 5 7.0201 ~~Departure~~Regulation ofFD ~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Disclosure.

AsFurnished as ~~reported~~Exhibit ~~in Item 5~~99.071 ~~below,~~to atthis ~~the~~report ~~2026~~is ~~annual~~a ~~meeting~~copy of ~~stockholders~~a corporate presentation of Daré Bioscience, Inc. (“Daré,” ~~“we,” “us,”~~ or ~~“our”) (~~the “~~Meeting~~Company”), ~~our~~dated ~~stockholders~~June ~~approved~~22, ~~an amendment to the Daré Bioscience~~2026, ~~Inc.~~which ~~2022~~is ~~Stock~~incorporated ~~Incentive~~herein ~~Plan (the “2022 Plan Amendment”) to increase the number of shares available for issuance thereunder~~ by ~~1,500,000~~reference. ~~Our~~The ~~board~~Company ofintends ~~directors previously approved the 2022 Plan Amendment, subject~~ to ~~and~~use ~~effective upon approval of~~ the ~~2022~~presentation ~~Plan Amendment by our stockholders. A brief description of the terms~~ and its ~~conditions~~contents ~~of the 2022 Plan Amendment is~~ in ~~the~~various ~~section~~meetings ~~entitled “Proposal 6 – To Approve an Amendment to the Company’s 2022 Stock Incentive Plan” of the definitive proxy statement for the Meeting filed~~ with ~~the~~securities ~~U.S.~~market ~~Securities~~participants and ~~Exchange~~others, ~~Commission~~commencing on ~~April~~June 2822, 2026 ~~(the “Proxy Statement”), which description is incorporated herein by reference~~. ~~A copy of the 2022 Plan Amendment is filed as an exhibit to this report and incorporated by reference herein.~~

~~Item~~The Company ~~5.07~~plans ~~Submission~~to make a copy of ~~Matters~~the topresentation aavailable ~~Vote~~in the “Investors” section of ~~Security~~its ~~Holders~~website (https://ir.darebioscience.com), on the page titled “Presentations, Events & Webcasts,” under the heading “Presentations.” Information contained in, or that can be accessed through, the Company’s website or any other website referenced in the presentation is not incorporated by reference into this report.

The information ~~Meeting~~in ~~was~~this ~~held~~Item on7.01 ~~June~~and ~~11,~~Exhibit ~~2026~~99.1 to this report is being furnished and ~~the~~shall ~~following~~not ~~proposals~~be ~~were~~deemed ~~voted~~to ~~upon~~be by“filed” ~~our~~for purposes ~~stockholders.~~of ~~The~~Section ~~proposals~~18 ~~are~~of ~~described~~the inSecurities ~~detail~~Exchange inAct of 1934, as amended (the ~~Proxy~~“Exchange ~~Statement.~~Act”), ~~Below~~or isotherwise asubject ~~brief~~to ~~description~~the liabilities of that section, ~~and~~nor shall such information be deemed to be incorporated by reference into any filing under the ~~final~~Exchange Act ~~results~~or the Securities Act of 1933, as amended, whether made before or after the ~~votes~~date ~~for~~hereof, ~~each~~regardless ~~proposal~~of any general incorporation by reference language in any such filing, except as the Company expressly sets forth by specific reference in such filing.

Proposal 1: Each of the director nominees identified in the table below was elected as a Class III director to hold office until our 2029 annual meeting of stockholders, and until their respective successor is duly elected and qualified, by the votes set forth below.

Nominee	Votes For	Votes Withheld	Broker Non-Votes
Gregory W. Matz, CPA	3,752,211	403,510	3,822,158
Sabrina Martucci Johnson	3,848,085	307,636	3,822,158

Proposal 2: Our stockholders ratified the appointment of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 by the votes set forth below.

Votes For						Votes Against						Abstentions						Broker Non-Votes
7,754,883						131,829						91,167						—

Proposal 3: Our stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement by the votes set forth below.

Votes For						Votes Against						Abstentions						Broker Non-Votes
3,625,596						458,662						71,463						3,822,158

Proposal 4: Our stockholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation of our named executive officers.

Every year			Every two years									Every three years						Abstentions						Broker Non-Votes
3,684,058						64,201						224,385						183,077						3,822,158

In light of the voting results, our board of directors has determined to hold an advisory vote on executive compensation every year until the next required say-on-frequency vote.

Proposal 5: Our stockholders approved, in accordance with Nasdaq rules, the potential future issuance of shares of our common stock under our existing equity line with Lincoln Park Capital Fund, LLC by the votes set forth below.

Votes For						Votes Against						Abstentions						Broker Non-Votes
3,771,709						325,568						58,444						3,822,158

Proposal 6: Our stockholders approved the 2022 Plan Amendment by the votes set forth below.

Votes For						Votes Against						Abstentions						Broker Non-Votes
3,497,228						609,746						48,747						3,822,158

Proposal 7: Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 5 if there were not sufficient votes to approve Proposal 5 by the votes set forth below. Because Proposal 5 was approved, the adjournment authorized by Proposal 7 was not necessary.

Votes For						Votes Against						Abstentions						Broker Non-Votes
3,650,815						448,085						56,821						3,822,158

Proposal 8: Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 if there were not sufficient votes to approve Proposal 6 by the votes set forth below. Because Proposal 6 was approved, the adjournment authorized by Proposal 8 was not necessary.

Votes For						Votes Against						Abstentions						Broker Non-Votes
3,531,653						570,999						53,069						3,822,158

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.	Description	~~Description~~
10.1		Amendment No. 2 to Daré Bioscience, Inc. 2022 Stock Incentive Plan
99.1	Daré Bioscience corporate presentation, dated June 22, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)	~~Cover Page Interactive Data File (embedded within the Inline XBRL document)~~

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DARÉ BIOSCIENCE, INC.

~~DARÉ BIOSCIENCE, INC.~~

Dated: June 12, 2026

By:

/s/ Sabrina Martucci Johnson

Dated: June 22, 2026

By:

/s/ Sabrina Martucci Johnson

Name:

Sabrina Martucci Johnson

~~Name:~~

~~Sabrina Martucci Johnson~~

Title:

President and Chief Executive Officer

~~Title:~~

~~President and Chief Executive Officer~~

-3-

Filing Compare · Dare Bioscience, Inc.